Manufacturers argue against mandatory training for opioid prescribers

摘要

Makers of opioid medications urged FDA to take a cautious approach to changing prescriber practices as the agency develops a risk evaluation and mitigation strategy (REMS) for some of these pain medications.rn"Taking certain steps, specifically a training-and-certification requirement to prescribe, would cause great harm to patients," said Johnson & Johnson's Susan Nicholson, representing the industry working group during a December 4 meeting in College Park, Maryland, convened by FDA.